Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | GALR3 | O60755 | 1/20 | 0.47 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.47 |
| ▸ | GPR183 | P32249 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.37 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18672267 | 0.94 | SMN1; SMN2 (0.45) | SMN1; SMN2LMNANPC1RAB9AMEN1 | |
| SCHEMBL18672266 | 0.92 | SMN1; SMN2 (0.53) | SMN1; SMN2LMNANPC1RAB9AMEN1 | |
| SCHEMBL11938602 | 0.91 | SMN1; SMN2 (0.46) | SMN1; SMN2LMNANPC1RAB9AMEN1 | |
| SCHEMBL14768943 | 0.90 | NPC1 (0.52) | SMN1; SMN2LMNANPC1RAB9AMEN1 | |
| SCHEMBL18672268 | 0.89 | SMN1; SMN2 (0.46) | SMN1; SMN2LMNANPC1RAB9AMEN1 | |
| SCHEMBL15596642 | 0.89 | SMN1; SMN2 (0.48) | SMN1; SMN2LMNANPC1RAB9AMEN1 | |
| SCHEMBL9827494 | 0.89 | SMN1; SMN2 (0.45) | SMN1; SMN2LMNANPC1RAB9AMEN1 | |
| SCHEMBL13694257 | 0.88 | SMN1; SMN2 (0.55) | SMN1; SMN2LMNANPC1RAB9AMEN1 | |
| SCHEMBL18672249 | 0.88 | SMN1; SMN2 (0.49) | SMN1; SMN2LMNANPC1RAB9AMEN1 | |
| SCHEMBL16901904 | 0.88 | SMN1; SMN2 (0.43) | SMN1; SMN2LMNANPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11565257-B2 | Stabilized radiolabelling reaction | GE HEALTHCARE LIMITED (GB) | 2023-01-31 | — | — | US | disclosed |
| US-20210023558-A1 | SOLID PHASE EXTRACTION | GE HEALTHCARE LIMITED (GB) | 2021-01-28 | — | — | US | disclosed |
| US-20210017098-A1 | STABILISED RADIOLABELLING REACTION | GE HEALTHCARE LIMITED (GB) | 2021-01-21 | — | — | US | disclosed |
| US-20200222562-A1 | STABILIZATION OF RADIOPHARMACEUTICAL COMPOSITIONS USING ASCORBIC ACID | LANTHEUS MEDICAL IMAGING, INC. (US) | 2020-07-16 | — | — | US | disclosed |
| EP-2419096-B1 | STABILIZATION OF RADIOPHARMACEUTICAL COMPOSITIONS USING ASCORBIC ACID | LANTHEUS MEDICAL IMAGING INC (US) | 2019-11-13 | — | — | EP | disclosed |
| EP-2257315-B1 | CONTRAST AGENTS FOR APPLICATIONS INCLUDING PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING INC (US) | 2019-10-23 | — | — | EP | disclosed |
| US-10245332-B2 | Contrast agents for applications including perfusion imaging | LANTHEUS MEDICAL IMAGING, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-10022462-B2 | Methods and apparatus for synthesizing imaging agents, and intermediates thereof | LANTHEUS MEDICAL IMAGING, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-20180133347-A9 | CONTRAST AGENTS FOR APPLICATIONS INCLUDING PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210023558-A1 | SOLID PHASE EXTRACTION | PNN, PDXK, TYMP | SMN1; SMN2 879/4885LMNA 1029/4885NPC1 2807/4885 |
| US-20200222562-A1 | STABILIZATION OF RADIOPHARMACEUTICAL COMPOSITIONS USING ASCORBIC ACID | TTPA, PROC, RBP1 | SMN1; SMN2 1500/4885LMNA 2154/4885NPC1 85/4885 |
| US-20210017098-A1 | STABILISED RADIOLABELLING REACTION | PDXK, MPI, PAICS | SMN1; SMN2 1017/4885LMNA 1848/4885NPC1 1799/4885 |
| US-20180133347-A9 | CONTRAST AGENTS FOR APPLICATIONS INCLUDING PERFUSION IMAGING | MCOLN1, CNR1, SLC5A7 | SMN1; SMN2 774/4885LMNA 4556/4885NPC1 169/4885 |
| US-10022462-B2 | Methods and apparatus for synthesizing imaging agents, and intermediates thereof | TNNI3, FABP3, MPI | SMN1; SMN2 2628/4885LMNA 3154/4885NPC1 1259/4885 |
| US-11565257-B2 | Stabilized radiolabelling reaction | PDXK, MPI, PAICS | SMN1; SMN2 911/4885LMNA 1625/4885NPC1 1725/4885 |
| US-10245332-B2 | Contrast agents for applications including perfusion imaging | MCOLN1, CNR1, SLC5A7 | SMN1; SMN2 774/4885LMNA 4556/4885NPC1 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.